Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and immune-mediated diseases [4] - The lead candidate is NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy, currently undergoing Phase 1b/2 trials in the U.S. and ex-U.S. [4] - NXC-201 has received Orphan Drug Designation from the US FDA and the EU EMA for AL Amyloidosis [4] Key Personnel - Dr. Raymond Comenzo has joined the scientific advisory board of ImmixBio's subsidiary, Nexcella, bringing extensive expertise in AL Amyloidosis [1][3] - Dr. Comenzo is recognized for his contributions to clinical trial guidelines and was the senior author of the Andromeda trial, which led to the first FDA-approved therapy for AL Amyloidosis [1][3] - He holds multiple prestigious positions, including Director of the Myeloma and Amyloid Program at Tufts Medical Center [3] Research and Development Focus - The company is advancing CAR-T therapy specifically for relapsed/refractory AL Amyloidosis, a condition currently lacking approved treatment options [2] - NXC-201 has shown no neurotoxicity and a short duration of cytokine release syndrome, indicating potential for expansion into other immune-mediated diseases [4]
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board